Puig N, Agulló C, Contreras T, Pérez J-J, Aires I, Calasanz M-J, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez M- Ángel, Bargay J, González-Rodríguez A-P, Alegre A, Escalante F, Iñigo M-B, de la Rubia J, Teruel A-I, de Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta J-J, Cedena M-T, Paiva B, Miguel JFS, Mateos M-V. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial. haematol [Internet]. 2020Sep.10 [cited 2024Nov.24];. Available from: https://haematologica.org/article/view/haematol.2024.285742